SEC Form 10-Q filed by Aura Biosciences Inc.
$AURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2024 | $21.00 | Buy | H.C. Wainwright |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 4/17/2023 | $38.00 | Buy | BTIG Research |
| 7/19/2022 | $26.00 | Mkt Outperform | JMP Securities |
| 11/24/2021 | $40.00 | Outperform | SVB Leerink |
| 11/23/2021 | $38.00 | Buy | BTIG Research |
| 11/23/2021 | Outperform | Cowen | |
| 11/23/2021 | $35.00 | Outperform | Evercore ISI |
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00
Scotiabank initiated coverage of Aura Biosciences with a rating of Sector Outperform
BTIG Research resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $38.00
Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC); Phase 1 Expansion Preparation in Progress Strong Cash Position Expected to Support Operations into 2H 2026 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the thir
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Aura Hosting Virtual Urologic Oncology Investor Event with Key Opinion Leaders at 4.30 pm ET Today BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), today announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer. The results were presented at The Retina Society Annual Meeting, on Thursday
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
HC Wainwright & Co. analyst Edward White initiates coverage on Aura Biosciences (NASDAQ:AURA) with a Buy rating and announces Price Target of $21.
Aura Biosciences (NASDAQ:AURA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Aura Biosciences beat estimated earnings by 73.0%, reporting an EPS of $-0.5 versus an estimate of $-1.82. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.04 which was followed by a 10.0% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for Aura Biosciences visit their earnings calendar here. This article was generated by Benzinga's automated content engin
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)